IRVING, Texas , Sept. 15, 2022 / PRNewswire / — Caris Life Sciences® (Caris), a molecular science and technology leader actively developing and delivering innovative solutions that revolutionize healthcare, today announced that Russ Denton has joined the company as a senior. vice president The President, General Counsel and Secretary, and will lead the corporate governance and legal activities of Caris.
Prior to joining Caris, he partnered with Denton Shearman & Sterling LLP, representing clients in M&A and equity financings, including partnering with Caris as outside counsel in connection with Caris Growth equity financing transactions. Prior to joining Shearman & Sterling, Denton was a partner at Andrews Kurth Kenyon LLP and legal counsel at Skadden, Arps, Slate, Meagher and Flom LLP.
"Caris is revolutionizing healthcare by providing new approaches to categorize, visualize and detect disease in ways not previously possible," said David D. Halbert, president and CEO of Caris Life Sciences. "We are pleased to welcome Russ Caris to the team, as his leadership and sound advice have served us well and will be invaluable as we continue to fulfill our mission."
"I am thrilled to join Caris and work at a pioneering healthcare company," said Denton. "I look forward to continuing to support Carys and her mission."
Mr. Denton received his J.D. from Stanford Law School and his J.D. from Duke University.
Information about Caris Life Sciences
Caris Life Sciences® (Caris) is a leading molecular science and technology company that actively develops and delivers innovative solutions that revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (whole exome and transcriptome sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris built the clinical genomic and computational cognitive databases necessary to explore and unravel the molecular complexity of disease. This information provides an unprecedented resource and an ideal avenue for basic and basic research to accelerate screening, diagnosis, monitoring, therapeutic selection, and discoveries to improve the human condition.
With a specific focus on cancer, Caris' market-leading molecular profiling suite evaluates DNA, RNA and protein to reveal molecular patterns that help patients, physicians and researchers better detect, diagnose and treat cancer. Caris' latest development is a blood-based circulating nucleic acid sequencing (cNAS) test that combines comprehensive molecular analysis (whole-exome sequencing and whole-blood transcriptome) with serial monitoring, making it the most powerful tool ever developed for liquid biopsy.
Based in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services in the United States, Europe, Asia and other international markets. For more information, visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).
Caris Life Sciences Media Contact: Lisa [email protected] 214.294.5606
To download the original media, see: https://www.prnewswire.com/news-releases/caris-life-sciences-announces-appointment-of-russ-denton-as-general-counsel-301625049.html
SOURCE Caris Life Sciences